Published in N Engl J Med on June 25, 2009
The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol (2009) 1.67
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol (2011) 1.11
Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood (2014) 0.95
Buckley-James boosting for survival analysis with high-dimensional biomarker data. Stat Appl Genet Mol Biol (2010) 0.89
Molecular pathology of lymphoma. Eye (Lond) (2012) 0.86
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res (2003) 10.28
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Genome of the marsupial Monodelphis domestica reveals innovation in non-coding sequences. Nature (2007) 7.91
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A (2003) 6.49
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Annotation, submission and screening of repetitive elements in Repbase: RepbaseSubmitter and Censor. BMC Bioinformatics (2006) 5.50
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci U S A (2002) 3.28
Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics (2006) 3.27
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Structural organization of bacterial RNA polymerase holoenzyme and the RNA polymerase-promoter open complex. Cell (2002) 3.21
Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum (2003) 3.05
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.80
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2.79
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Extranodal marginal zone lymphoma of the ocular adnexa. Blood (2009) 2.65
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52
Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood (2008) 2.36
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32
Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res (2010) 2.25
Amino acid runs in eukaryotic proteomes and disease associations. Proc Natl Acad Sci U S A (2002) 2.17
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10
Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. Am J Clin Pathol (2010) 2.10
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol (2009) 2.09
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood (2005) 1.99
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood (2006) 1.94
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
Boolean implication networks derived from large scale, whole genome microarray datasets. Genome Biol (2008) 1.91
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol (2007) 1.88
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol (2004) 1.74
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood (2003) 1.73
Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol (2006) 1.72
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A (2011) 1.71
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma (2009) 1.71
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68
Primary bone lymphoma--the University of Miami experience. Leuk Lymphoma (2010) 1.68
Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma (2009) 1.68
Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray. J Clin Microbiol (2007) 1.67
Discovering biological progression underlying microarray samples. PLoS Comput Biol (2011) 1.65
Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A (2012) 1.60
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A (2003) 1.58
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res (2008) 1.58
Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet (2004) 1.56
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood (2008) 1.55
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54
Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leuk Lymphoma (2013) 1.52
Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A (2002) 1.49
T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. PLoS Biol (2003) 1.49
Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res Ther (2012) 1.49
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood (2004) 1.48
HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood (2003) 1.47
Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma (2010) 1.46
[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma (2009) 1.44
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41
Association between non-Hodgkin lymphoma and renal cell carcinoma. Leuk Lymphoma (2011) 1.41
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood (2002) 1.40
Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood (2005) 1.38
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res (2008) 1.36
PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood (2008) 1.32
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29